Verve Therapeutics
VERV
VERV was delisted on the 24th of July, 2025.
166 hedge funds and large institutions have $444M invested in Verve Therapeutics in 2024 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 63 increasing their positions, 54 reducing their positions, and 26 closing their positions.
22% more capital invested
Capital invested by funds: $365M → $444M (+$79.3M)
17% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 54
3.96% more ownership
Funds ownership: 88.95% → 92.92% (+4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less funds holding
Funds holding: 174 → 166 (-8)
21% less call options, than puts
Call options by funds: $734K | Put options by funds: $926K
23% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$35.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.86M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$7.8M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.63M |
| 5 |
BlackRock
New York
|
+$1.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$6.94M |
| 2 |
Millennium Management
New York
|
-$5.89M |
| 3 |
State Street
Boston,
Massachusetts
|
-$5.74M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$3.47M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$3.16M |
VERV Hedge Fund Activity: Q4 2024 in Review
166 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q4 2024, worth a combined $444M — up 22% from $365M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of VERV and 20 opened new positions — a net loss of 6 holders — while 54 trimmed existing stakes and 63 added.
The largest buyer was BVF Inc, adding an estimated $35.3M. The largest seller was JP Morgan Chase, cutting an estimated $6.94M.
- 166 institutional investors held Verve Therapeutics (VERV) as of Q4 2024, down from 174 in Q3 2024.
- Funds reported $444M of Verve Therapeutics stock for Q4 2024, up 22% quarter-over-quarter.
- 20 funds opened new Verve Therapeutics positions in Q4 2024 and 26 closed out, a net change of -6 holders.
- The largest Verve Therapeutics buyer in Q4 2024 was BVF Inc, an estimated $35.3M added.
- The largest Verve Therapeutics seller in Q4 2024 was JP Morgan Chase, an estimated $6.94M sold.
Based on aggregated 13F filings for Q4 2024.